Drug intelligence / Profile preview

BMS-986184

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

BMS-986184 is a human, second-generation monoclonal antibody that targets interferon-gamma-induced protein 10 (IP-10), also known as chemokine CXCL10. It was developed by Bristol Myers Squibb for the treatment of inflammatory diseases, with a primary focus on ulcerative colitis. The drug acts as an inhibitor of CXCL10, thereby modulating immune cell trafficking and inflammation. Clinical development included first-in-human studies to characterize its pharmacokinetics and target engagement in healthy participants[1][2][7]. However, clinical trials for ulcerative colitis were discontinued at Phase I[2].

Other names: BMS 986184BMS986184BMS-986184

Targets

CXCL10 (C-X-C Motif Chemokine Ligand 10)

Beyond the preview

Go deeper on BMS-986184.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986184.

Explore the full profile